The Cancer With the Lowest Survival Rate May Finally Have an Early Test
Summary
Researchers in Japan developed a blood test that detects early-stage pancreatic cancer by measuring gene activity in immune cells. This test identified 90% of early cases, outperforming the current standard marker, which only detected 10%.Key Facts
- Pancreatic cancer has one of the lowest survival rates, with a five-year survival rate around 13% in the U.S. and 8.5% in Japan.
- Early-stage pancreatic cancer makes up only 2-3% of diagnoses because it is hard to detect before symptoms appear.
- The new blood test measures gene activity in immune cells that change when pancreatic tumors are present.
- This gene expression test detected 9 out of 10 early-stage pancreatic cancer cases in the study.
- The standard tumor marker CA19-9 detected only 1 out of 10 early cases.
- A combined test using both gene activity and CA19-9 detected 60% of cases with high accuracy.
- Experts say the test is promising but needs validation in larger and more diverse groups of patients.
- Early detection could increase chances for surgery and improve survival rates.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
